Claims for Patent: 8,911,960
✉ Email this page to a colleague
Summary for Patent: 8,911,960
Title: | Method for identifying idiopathic pneumonia progression by measuring the level of mannose-binding protein C |
Abstract: | A method for characterizing the risk a subject will develop an autoimmune and/or alloimmune disease following tissue transplant includes obtaining a biological sample from the subject, wherein the subject has received the tissue transplant determining in the biological sample a level of at least one protein selected from Tables 1-4, comparing the measured level of the at least one protein to a control value, and characterizing a subject as at greater risk of developing an autoimmune disease and/or alloimmune disease if the level of at least one protein determined is increased or decreased compared to the control value. |
Inventor(s): | Chance; Mark (Chagrin Falls, OH), Cooke; Kenneth (Solon, OH), Schlatzer; Daniela (Lakwood, OH) |
Assignee: | Case Western Reserve University (Cleveland, OH) |
Application Number: | 13/375,523 |
Patent Claims: | 1. A method for identifying idiopathic pneumonia syndrome (IPS) progression in a subject following allogeneic hematopoietic stem cell
transplantation, the method comprising: obtaining a biological sample from the subject, wherein the biological sample comprises a sample of blood, plasma, serum, or bronchoalveolar lavage fluid, wherein the subject has received the allogeneic
hematopoietic stem cell transplantation; and determining in the biological sample a level of Mannose-binding protein C; comparing the measured level of Mannose-binding protein C to a control level prior to transplantation; and identifying the IPS as
progressing if the level of Mannose-binding protein C determined is decreased at least about 5% compared to the control level.
2. The method of claim 1, wherein a decrease of at least about 20% in the determined level of Mannose-binding protein C compared to the control level characterizes the IPS in the subject as progressing. 3. The method of claim 1, wherein the IPS is a subtype of idiopathic pneumonia syndrome that is responsive to treatment by a TNF-.alpha. inhibitor, wherein the TNF-.alpha. inhibitor is selected from the group consisting of etanercept, infliximab, adalimumab, certolizumab pegol, gohmumab (simponi), lenercept, semapimod, pentoxifylline, thalidomide, and benzopyranes. |
Details for Patent 8,911,960
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Janssen Biotech, Inc. | REMICADE | infliximab | For Injection | 103772 | 08/24/1998 | ⤷ Try a Trial | 2029-06-01 |
Immunex Corporation | ENBREL | etanercept | For Injection | 103795 | 11/02/1998 | ⤷ Try a Trial | 2029-06-01 |
Immunex Corporation | ENBREL | etanercept | For Injection | 103795 | 05/27/1999 | ⤷ Try a Trial | 2029-06-01 |
Immunex Corporation | ENBREL | etanercept | Injection | 103795 | 09/27/2004 | ⤷ Try a Trial | 2029-06-01 |
Immunex Corporation | ENBREL | etanercept | Injection | 103795 | 02/01/2007 | ⤷ Try a Trial | 2029-06-01 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.